Hydrogen Bromide → Citalopram

HRID 353603

반응식

HRID 353603 반응식
[CH3:1][N:2]([CH3:8])[CH2:3][CH2:4][CH2:5][Mg]Cl.Cl[CH2:10][C:11]1[CH:12]=[C:13]([CH:16]=[CH:17][C:18]=1[C:19](=[O:27])[C:20]1[CH:25]=[CH:24][C:23]([F:26])=[CH:22][CH:21]=1)[C:14]#[N:15].Br>COCCOC>[CH3:1][N:2]([CH3:8])[CH2:3][CH2:4][CH2:5][C:19]1([C:20]2[CH:25]=[CH:24][C:23]([F:26])=[CH:22][CH:21]=2)[C:18]2[C:11](=[CH:12][C:13]([C:14]#[N:15])=[CH:16][CH:17]=2)[CH2:10][O:27]1

참가 물질

5

반응물 3

HCID 260Hydrogen BromideHCID 99434343-Chloromethyl-4-(4-fluoro-benzoyl)-benzonitrileHCID 178483494HCID 178483494, 화합물

생성물 1

HCID 2771Citalopram수율 75%

시약·촉매·용매 1

HCID 80711,2-Dimethoxyethane용매

실험 절차

A solution of freshly prepared 3-dimethylaminopropylmagnesium chloride (0.6M in THF, 7.6 ml) was added to a cooled solution of 3-chloromethyl-4-(4-fluoro-benzoyl)-benzonitrile (0.5 g) in ethylene glycol dimethyl ether (4 ml) so that the temperature did not raise above −4° C. The mixture was stirred for 30 minutes at −15° C. and 100 minutes at room temperature before 0.5N hydrobromic acid was added to adjust the pH to 10. The phases were separated and the aqueous phase was extracted twice with toluene (25 ml). The combined organic phases were dried over sodium sulfate, filtered and dried in vacuo to give a viscous oil (0.44 g, 75%). Spectral and analytical data were in accordance with the literature.

후처리

  1. temperaturedid not raise above −4° C
  2. additionwas added
  3. customThe phases were separated
  4. extractionthe aqueous phase was extracted twice with toluene (25 ml)
  5. dry with materialThe combined organic phases were dried over sodium sulfate
  6. filtrationfiltered
  7. customdried in vacuo

출처 및 근거

ORD 기록
ord-48986394d87847039175838d69f7d657
출처 데이터셋
uspto-grants-2004_06
특허 번호
US06753433B2

연결된 노트

불러오는 중…